Allarity Therapeutics, Inc.
ALLR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,096 | $7,103 | $6,930 | $14,196 |
| G&A Expenses | $11,442 | $10,026 | $9,962 | $12,360 |
| SG&A Expenses | $11,442 | $10,026 | $9,962 | $12,360 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $9,703 | $0 | $17,571 | $0 |
| Operating Expenses | $27,241 | $17,129 | $34,463 | $26,556 |
| Operating Income | -$27,241 | -$17,129 | -$34,463 | -$26,556 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,345 | $5,311 | $16,884 | $41 |
| Pre-Tax Income | -$24,896 | -$11,818 | -$17,579 | -$26,515 |
| Tax Expense | -$381 | $83 | -$1,521 | $133 |
| Net Income | -$24,515 | -$11,901 | -$16,058 | -$26,648 |
| % Margin | – | – | – | – |
| EPS | -15.791 | -6,153.264 | -1,856,055 | -3,520,104 |
| % Growth | 99.7% | 99.7% | 47.3% | – |
| EPS Diluted | -15.791 | -6,153.264 | -1,856,055 | -3,520,104 |
| Weighted Avg Shares Out | 1,607 | 3 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1,607 | 3 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $533 | $22 | $30 | $0 |
| Interest Expense | $653 | $498 | $223 | $640 |
| Depreciation & Amortization | $9 | $37 | $60 | $106 |
| EBITDA | -$24,234 | -$11,283 | -$17,296 | -$25,769 |
| % Margin | – | – | – | – |